{"id":16567,"date":"2026-11-07T00:27:47","date_gmt":"2026-11-07T00:27:47","guid":{"rendered":"https:\/\/financialnewsspot.com\/?p=16567"},"modified":"2026-11-07T00:27:49","modified_gmt":"2026-11-07T00:27:49","slug":"a-moonshot-idea-the-story-behind-canadas-largest-innovation-hub","status":"publish","type":"post","link":"https:\/\/financialnewsspot.com\/?p=16567","title":{"rendered":"A moonshot idea: The story behind Canada\u2019s largest innovation hub"},"content":{"rendered":"<div style=\"text-align:center\"><\/div><p> <br \/>\n<\/p>\n<p>When it comes to improving the well-being of Canadians, few people have done more than Dr. Calvin Stiller. A visionary in the field of organ transplantation, he established the multi-organ transplant service at UHN and helped develop a key protocol to mitigate rejection in kidney recipients; he also discovered the benefits of using immunosuppressants to treat type 1 diabetes. He co-founded the Robarts Research Institute, developed several funds to spur public and private sector partnerships in supporting groundbreaking medical discoveries and was the catalyst for Ontario\u2019s first telemedicine service.<\/p>\n<p>As all that breakthrough work suggests, Stiller, who was named an officer of the Order of Canada in 2011, is a lifelong champion of medical innovation. That ethos is what led him to connect with Dr. John Evans \u2014 initially to provide funding for Allelix, Canada\u2019s first public biotech firm, where Evans served as CEO and executive chairman and, ultimately, as one of the essential sparks that led to the founding of MaRS in 2001.<\/p>\n<p>Here, Stiller looks back at a quarter century of innovation and shares his memories of how all that critical infrastructure came to be.<\/p>\n<figure id=\"attachment_260294\" aria-describedby=\"caption-attachment-260294\" style=\"width: 1500px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/marsdd-public-files.s3.ca-central-1.amazonaws.com\/wp-content\/uploads\/2026\/11\/06090950\/blog_John-Evans-and-Cal-Stiller.webp\" alt=\"Dr. John Evans and Dr. Calvin Stiller were instrumental in the creation of MaRS Discovery District. \" width=\"1500\" height=\"750\" class=\"size-full wp-image-260294\" \/><figcaption id=\"caption-attachment-260294\" class=\"wp-caption-text\">Dr. John Evans and Dr. Calvin Stiller were instrumental in the creation of MaRS&nbsp;Discovery&nbsp;District.<\/figcaption><\/figure>\n<p><strong>We often talk about the establishment of MaRS as though it was a sudden epiphany. But there was quite a bit of runway \u2014 or perhaps \u201cscaffolding\u201d is more apt in this context \u2014 that helped Dr. John Evans get his big idea off the ground\u2026 and much of that involved you. Can you tell us a bit about that journey?<\/strong><\/p>\n<p>I don\u2019t think I\u2019ve ever told the story about how John Evans and I came together. It was a converging of interests and boards that we sat on \u2014 and passion. I was a professor at Western, and was committed to the whole idea of translating ideas from the laboratory to the bedside to the community, and then paying back into the system. Henry Friesen, who was the president of the Medical Research Council (the predecessor of the Canadian Institutes of Health Research) came to me in 1994 and said, \u201cLook, we don\u2019t have money that\u2019s being invested from the private sector in the area of medical research. Will you take a leave of absence from the university for a few years and raise money in the venture capital area?\u201d I formed the Canadian Medical Discoveries Fund, and everyone thought it was going to be a failure. Henry Friesen went on the road with me, and we raised $540 million. It was unheard of \u2014 we had 100,000 individuals who paid $5,000 apiece. So we started investing this in small companies and scientists across the country.<\/p>\n<p>[After Premier Mike Harris was elected in 1995], Michael Gurley became the deputy minister of finance. Well, Mike had been on the board of Robarts Research Institute, which I helped found. About two years in, I said, \u201cMike, you\u2019ve dismantled so much in Ontario, it\u2019s time for you to do something grand and glorious, something noble, something that inspires people \u2014 like Kennedy putting a man on the moon.\u201d<\/p>\n<p>A few months later, a car came up my driveway and in it was Mike Gurley. He sat down in my kitchen and said, \u201cCal, I want to put forward to the premier to do something significant in the area of research and the translation of research.\u201d He\u2019d bought into my idea that we should not be calling these grants, but investments, and we should be expecting ROI \u2014 that we should find ways to translate them into commercial and social impact. He said he was starting a fund and asked how big it should be. I said it should be $100 for every man, woman and child in Ontario. He wanted me to chair the fund, and I couldn\u2019t say no. And that\u2019s how I met Ken Knox. We became like brothers.<\/p>\n<p><strong>And that fund presaged MaRS, correct?<\/strong><\/p>\n<p>That was the Ontario Research and Development Challenge Fund, and it was the first foundational stone for MaRS, because it was the first time that a provincial government had supported and invested in research \u2014 the template was that you had a private sector partner. From the private side, I\u2019d raised $500 million for the Canadian Medical Discoveries Fund. Those two things came together. The biggest investment that the Canadian Medical Discoveries made was in Allelix, the first public biotechnology company in Canada, which was formed by John Evans.<\/p>\n<p><strong>Was that the first time you\u2019d connected with Dr. Evans?<\/strong><\/p>\n<p>I\u2019d known about John, but I didn\u2019t <em>know<\/em> him. Again, we became like family. We were together or on the phone with each other virtually every day. We wanted to find a site for Allelix in Toronto, and we thought the place to do that was right in the heart of the city, down on University Avenue. That was the spring of 2000. In June of that year, Ken Knox and I went to a big biotech meeting in Boston and we visited Kendall Square, which is an area in juxtaposition to MIT and Harvard, in the old Navy Yard, where big biotech companies were located and young companies were forming. As we walked down the street, Ken and I turned to each other and said \u201cWe\u2019ve got to do this in Toronto.\u201d<\/p>\n<p>When we got back, Ken and I arranged to have a meeting at the Ontario Hydro Building in the president\u2019s office on the 11th floor, which now faces the MaRS Centre. John Evans and I happened to be on the board of Paul Reichmann\u2019s big real estate company [Olympia &amp; York], so I called Paul and said, \u201cThis is big stuff; we need a real Moses figure to be involved,\u201d and invited him. I remember Paul going over to the window, looking down over the old Toronto General Hospital site and imagining developing it from Elizabeth Street and beyond. At the end of the meeting, we began to get excited that this was doable. They were going to start working on this file, but they said we needed to give it a name. Now, remember the earlier story I told about the moon launch? They were calling this the lunar file. Well, Mike Gurley was in the corner of the room and he says, \u201cYou\u2019ve already got an idea \u2014 call it Mars.\u201d<\/p>\n<p><strong>So the name predated the acronym?<\/strong><\/p>\n<p>Yeah. About a week later, John and I were travelling and got caught in a snowstorm in Chicago. We had to spend the night there. John and I tried to sleep on this wooden bench, and in the middle of the night, he sat up, pulled out a pad of paper and said, \u201cWell, Cal, we\u2019re not getting any sleep. Let\u2019s start working.\u201d If we could get 11 people to put up a million dollars apiece, that would be enough to go to the government and ask them to match it \u2014 and that would be enough for a down payment on the land. We decided that Mars needed to get a real name. Joe Rotman knew the guru of branding, Bruce Mau, and arranged for him to come in pro bono. When I explained what we were trying to do, Bruce asked, \u201cWhat do you call it now?\u201d I said, \u201cWe have a file name. It\u2019s Mars.\u201d Bruce looks away and says \u201cI can see it now: Mars, the greatest address on Earth. Now, figure out what Mars stands for.\u201d We were trying to find a place for medical and related sciences \u2014 and so that\u2019s what MaRS is.<\/p>\n<p><strong>Do you have any insights into how all those pieces fell into place so smoothly?<\/strong><\/p>\n<p>The reason we succeeded was that we had a parallel operating group. We were kind of the private sector\u2019s political side, right? We were haranguing politicians, hectoring them, bribing them with words. But we had a really smart group on the inside \u2014 Mike Gurley, who was the deputy minister of finance, Mike Harris\u2019s chief of staff David Lindsay, who became deputy minister of energy and infrastructure, Michele Noble, who was the secretary of the management board of cabinet, and Ken Knox, who was the deputy minister of energy, science and technology, at the head. That committee of four kept everything moving along the track of the civil service. But Ken Knox is the unsung hero of this whole thing, because he worked like crazy.<\/p>\n<p><strong>Even today, it\u2019s not always easy to capture the essence of MaRS in an elevator pitch. How did you articulate that at the time?<\/strong><\/p>\n<p>It was like pulling teeth. Now, one thing that was a bit of a problem was that in 2000, there was a dot-com bust and the market crashed. Early startups had drummed up a lot of money, and then \u2026 nothing happened. Early-stage financing was not in vogue. We eventually overcame that. And although medical and related sciences was our base, there was not much in the area of medical developments in MaRS for, frankly, the first 10 years. But of course, with the figures you have now, nobody should have any remaining doubts.<\/p>\n<p><strong>This whole thing was catalyzed, in part, by your moon-launch idea \u2014 the notion of creating the conditions to, say, find a cure for cancer. Looking forward, where should MaRS be focusing to meet the moment in a similarly ambitious way?<\/strong><\/p>\n<p>One of the things I used to say was that the two greatest discoveries in medicine were DNA and the computer chip, because without the computer chip, our understanding of DNA would never have been able to be developed. That convergence of those different disciplines was critical. Today, AI is completely changing the discovery and application of new drugs and processes in medicine. We need to pick an area, and I think that is medicine, and a technology, which is the large language model of AI, and put those two in an intense partnership.<\/p>\n<p><strong>As the landscape has evolved in tandem with this technology, we\u2019ve seen a huge increase in people accessing misinformation and disinformation, especially when it comes to health and medicine. As a physician, what\u2019s your take on this issue? <\/strong><\/p>\n<p>Vetting is everything. You\u2019re not just going to buy a good-looking Rolex watch right on Yonge Street, because you\u2019re not getting it from the right source. Open that thing up and it\u2019ll fall apart. We\u2019ve got to develop a source of truth. Ultimately, a tool should be developed that is a purifier of ideas and information, a base that will be able to sort out that which is popular or widespread from that which is true. But who\u2019s working on that? I don\u2019t know. Limiting the spread of information is not in the interest, frankly, of a lot of the users of the software side of things.<\/p>\n<p><strong>Well, the most progress in that area is arguably happening in academia, because there\u2019s a vested interest in facts and objectivity. If you go back to the idea of MaRS being at the crux of enterprise and academia and government and working to ensure that these tools reach the market\u2026 <\/strong><\/p>\n<p>So, you just described one of the most important new initiatives that should come out of MaRS. There should be, there should be a virtual institute of authenticity, of truth, of reality-based information, where you bring the smartest people from academia together with your AI people and develop a vetting mechanism.<\/p>\n<p>Now that\u2019s something that I could go out and fundraise for.<\/p>\n<p>&nbsp;<\/p>\n<h6><strong><em>Canada\u2019s largest urban innovation hub is celebrating 25 years of discoveries and breakthroughs. Read more <a target=\"_blank\" href=\"https:\/\/www.marsdd.com\/magazine-issues\/mars25\/\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/em><\/strong><\/h6>\n<p><small>Photo credit: MaRS Discovery District<\/small><\/p>\n<p>The post <a target=\"_blank\" href=\"https:\/\/www.marsdd.com\/magazine\/a-moonshot-idea-the-story-behind-canadas-largest-innovation-hub\/\">A moonshot idea: The story behind Canada\u2019s largest innovation hub<\/a> appeared first on <a target=\"_blank\" href=\"https:\/\/www.marsdd.com\">MaRS Discovery District<\/a>.<\/p>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.marsdd.com\/magazine\/a-moonshot-idea-the-story-behind-canadas-largest-innovation-hub\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>When it comes to improving the well-being of Canadians, few people have done more than Dr. Calvin Stiller. A visionary in the field of organ transplantation, he established the multi-organ transplant service at UHN and helped develop a key protocol to mitigate rejection in kidney recipients; he also discovered the benefits of using immunosuppressants to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":16568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"tdm_status":"","tdm_grid_status":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[63],"tags":[],"class_list":["post-16567","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health"],"acf":[],"_links":{"self":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16567"}],"version-history":[{"count":1,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16567\/revisions"}],"predecessor-version":[{"id":16569,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16567\/revisions\/16569"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/media\/16568"}],"wp:attachment":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}